Evidence map›Paper›PMID 30716386›Full record

ArticleCellular signalling2019

Minocycline inhibits PDGF-BB-induced human aortic smooth muscle cell proliferation and migration by reversing miR-221- and -222-mediated RECK suppression.

Yusuke Higashi, Srinivas Mummidi, Sergiy Sukhanov, Tadashi Yoshida, Makoto Noda, Patrice Delafontaine, Bysani Chandrasekar

Open access · greenAbstract read
In one paragraph

Article in Cellular signalling, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Yusuke HigashiMedicine/Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, MO, USA; Department of Medical Pharmacology and Physiology, University of Missouri School of Medicine, Columbia, MO, USA.
Srinivas MummidiDepartment of Human Genetics, South Texas Diabetes and Obesity Institute, The University of Texas Rio Grande Valley School of Medicine, Edinburg, TX, USA; Medicine/Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, MO, USA.
Sergiy SukhanovMedicine/Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, MO, USA; Department of Medical Pharmacology and Physiology, University of Missouri School of Medicine, Columbia, MO, USA.
Tadashi YoshidaMedicine/Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, MO, USA; Department of Medical Pharmacology and Physiology, University of Missouri School of Medicine, Columbia, MO, USA.
Makoto NodaDepartment of Molecular Oncology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8501, Japan.
Patrice DelafontaineMedicine/Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, MO, USA.
Bysani ChandrasekarMedicine/Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, MO, USA; Department of Medical Pharmacology and Physiology, University of Missouri School of Medicine, Columbia, MO, USA; Research Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA; Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, USA. Electronic address: chandrasekarb@health.missouri.edu.
University of Missouri · USKyoto University · JPThe University of Texas Rio Grande Valley · USUniversity of Missouri Hospital · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
Insulin-Like Growth Factor-1and AtherosclerosisR01HL070241 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI PATRICE DELAFONTAINE · 2003 to 2026
$10.1M
ANGIOTENSIN II, IGF-1 AND SKELETAL MUSCLE ATROPHYR01HL080682 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI DELAFONTAINE, PATRICE · 2007 to 2015
$3.3M
GAPDH, DNA Repair and AtherosclerosisR01HL142796 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI SUKHANOV, SERGIY · 2019 to 2022
$1.5M
Impact of disease associated noncoding polymorphisms on post-transcriptional gene regulationR01AI119131 · NIAID · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI MUMMIDI, SRINIVAS · 2016 to 2019
$1.5M
12/15-LIPOXYGENASE, INSULIN-LIKE GROWTH FACTOR-1 AND ATHEROSCLEROSISR21HL113705 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI SUKHANOV, SERGIY · 2013 to 2014
$399k
TRAF3IP2 in Ischemic Heart DiseaseI01BX002255 · VA · SOUTHEAST LOUISIANA VETERANS HEALTH CARE · PI BYSANI, CHANDRASEKAR · 2014 to 2017
–
BLRD Research Career Scientist Award ApplicationIK6BX004016 · VA · HARRY S. TRUMAN MEMORIAL VA HOSPITAL · PI Chandrasekar Bysani · 2018 to 2026
–
TRAF3IP2 in Adverse Cardiac Remodeling and Heart FailureI01BX004220 · VA · HARRY S. TRUMAN MEMORIAL VA HOSPITAL · PI BYSANI, CHANDRASEKAR · 2018 to 2021
–
BLRD VA I01 BX002255BLRD VA I01 BX004220BLRD VA IK6 BX004016NHLBI NIH HHS R01 HL070241NHLBI NIH HHS R01 HL080682NHLBI NIH HHS R01 HL142796NHLBI NIH HHS R21 HL113705NIAID NIH HHS R01 AI119131NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

Minocycline, a tetracycline antibiotic, is known to exert vasculoprotective effects independent of its anti-bacterial properties; however the underlying molecular mechanisms are not completely understood. Reversion Inducing Cysteine Rich Protein with Kazal Motifs (RECK) is a cell surface expressed, membrane anchored protein, and its overexpression inhibits cancer cell migration. We hypothesized that minocycline inhibits platelet-derived growth factor (PDGF)-induced human aortic smooth muscle cell (SMC) proliferation and migration via RECK upregulation. Our data show that the BB homodimer of recombinant PDGF (PDGF-BB) induced SMC migration and proliferation, effects significantly blunted by pre-treatment with minocycline. Further investigations revealed that PDGF-BB induced PI3K-dependent AKT activation, ERK activation, reactive oxygen species generation, Nuclear Factor-κB and Activator Protein-1 activation, microRNA (miR)-221 and miR-222 induction, RECK suppression, and matrix metalloproteinase (MMP2 and 9) activation, effects that were reversed by minocycline. Notably, minocycline induced RECK expression dose-dependently within the therapeutic dose of 1-100 μM, and silencing RECK partially reversed the inhibitory effects of minocycline on PDGF-BB-induced MMP activation, and SMC proliferation and migration. Further, targeting MMP2 and MMP9 blunted PDGF-BB-induced SMC migration. Together, these results demonstrate that minocycline inhibits PDGF-BB-induced SMC proliferation and migration by restoring RECK, an MMP inhibitor. These results indicate that the induction of RECK is one of the mechanisms by which minocycline exerts vasculoprotective effects.

Indexed as

Cell MovementCell ProliferationGPI-Linked ProteinsHumansMicroRNAsMinocyclineMuscle, Smooth, VascularMyocytes, Smooth MusclePhosphatidylinositol 3-KinasesGPI-Linked ProteinsMicroRNAsMinocyclineMIR221, humanMIR222, humanPhosphatidylinositol 3-KinasesRECK protein, humanMigrationMitogenesisMMPPDGFRECKRestenosisVascular proliferative diseases

Identifiers

PMID30716386
PMCPMC6732797
OpenAlexW2914810284

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.